These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 8886299)

  • 1. Effect of acute tryptophan depletion on behavioral, cardiovascular, and hormonal sensitivity to cholecystokinin-tetrapeptide challenge in healthy volunteers.
    Koszycki D; Zacharko RM; Le Melledo JM; Young SN; Bradwejn J
    Biol Psychiatry; 1996 Oct; 40(7):648-55. PubMed ID: 8886299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pentagastrin infusions in patients with panic disorder. I. Symptoms and cardiovascular responses.
    Abelson JL; Nesse RM
    Biol Psychiatry; 1994 Jul; 36(2):73-83. PubMed ID: 7948449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peptides and anxiety: a dose-response evaluation of pentagastrin in healthy volunteers.
    McCann UD; Slate SO; Geraci M; Uhde TW
    Anxiety; 1994-1995; 1(6):258-67. PubMed ID: 9160584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A dose-ranging study of the behavioral and cardiovascular effects of CCK-tetrapeptide in panic disorder.
    Bradwejn J; Koszycki D; Annable L; Couëtoux du Tertre A; Reines S; Karkanias C
    Biol Psychiatry; 1992 Nov; 32(10):903-12. PubMed ID: 1467375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Behavioral, cardiovascular, and neuroendocrine profiles following CCK-4 challenge in healthy volunteers: a comparison of panickers and nonpanickers.
    Koszycki D; Zacharko RM; Le Mellédo JM; Bradwejn J
    Depress Anxiety; 1998; 8(1):1-7. PubMed ID: 9750972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of loudness dependency of auditory evoked potentials on the panic response to CCK-4.
    Eser D; Leicht G; Baghai T; Pogarell O; Schüle C; Karch S; Nothdurfter C; Rupprecht R; Mulert C
    J Psychiatr Res; 2009 Jan; 43(4):393-400. PubMed ID: 18534623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The ventilatory response to cholecystokinin tetrapeptide in healthy volunteers.
    Katzman MA; Duffin J; Shlik J; Bradwejn J
    Neuropsychopharmacology; 2002 Jun; 26(6):824-31. PubMed ID: 12007753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. One milligram of lorazepam does not decrease anxiety induced by CCK-4 in healthy volunteers: investigation of neural correlates with BOLD MRI.
    Schunck T; Mathis A; Erb G; Namer IJ; Hode Y; Demazières A; Luthringer R
    J Psychopharmacol; 2011 Jan; 25(1):52-9. PubMed ID: 20498136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder. Clinical and behavioral findings.
    Bradwejn J; Koszycki D; Shriqui C
    Arch Gen Psychiatry; 1991 Jul; 48(7):603-10. PubMed ID: 2069490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Copeptin - A potential endocrine surrogate marker of CCK-4-induced panic symptoms?
    Demiralay C; Agorastos A; Yassouridis A; Jahn H; Wiedemann K; Kellner M
    Psychoneuroendocrinology; 2017 Feb; 76():14-18. PubMed ID: 27871026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CCK-B receptor gene and response to cholecystokinin-tetrapeptide in healthy volunteers.
    Koszycki D; Prichard Z; Fiocco AJ; Shlik J; Kennedy JL; Bradwejn J
    Peptides; 2012 May; 35(1):9-13. PubMed ID: 22414867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of cholecystokinin tetrapeptide on respiratory resistance in healthy volunteers.
    Shlik J; Vasar V; Aluoja A; Kingisepp PH; Jagomägi K; Vasar E; Rägo L; Bradwejn J
    Biol Psychiatry; 1997 Aug; 42(3):206-12. PubMed ID: 9232213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased ACTH concentrations associated with cholecystokinin tetrapeptide-induced panic attacks in patients with panic disorder.
    Ströhle A; Holsboer F; Rupprecht R
    Neuropsychopharmacology; 2000 Mar; 22(3):251-6. PubMed ID: 10693152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute effects of cholecystokinin tetrapeptide on brain stem auditory evoked potentials in healthy volunteers.
    Gunnarsson T; Mahoney C; Shlik J; Bradwejn J; Knott V
    Pharmacopsychiatry; 2003 Sep; 36(5):181-6. PubMed ID: 14571352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In healthy volunteers responses to challenge with cholecystokinin tetrapeptide differ between administration during REM and delta sleep.
    Kronenberg G; Schredl M; Fiedler K; Heuser I
    Depress Anxiety; 2001; 14(2):141-4. PubMed ID: 11668667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Megestrol attenuates the hormonal response to CCK-4-induced panic attacks.
    Raedler TJ; Jahn H; Goedeken B; Gescher DM; Kellner M; Wiedemann K
    Depress Anxiety; 2006; 23(3):139-44. PubMed ID: 16470820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tryptophan depletion does not modify response to CCK-4 challenge in patients with panic disorder after treatment with citalopram.
    Tõru I; Shlik J; Maron E; Vasar V; Nutt DJ
    Psychopharmacology (Berl); 2006 May; 186(1):107-12. PubMed ID: 16541242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of the beta-noradrenergic system in cholecystokinin-tetrapeptide-induced panic symptoms.
    Le Mellédo JM; Bradwejn J; Koszycki D; Bichet DG; Bellavance F
    Biol Psychiatry; 1998 Sep; 44(5):364-6. PubMed ID: 9755359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular effects of cholecystokinin-4 are mediated by the cholecystokinin-B receptor subtype in the conscious guinea pig and dog.
    Fossa AA; DePasquale MJ; Morrone J; Zorn SH; Bryce D; Lowe JA; McLean S
    J Pharmacol Exp Ther; 1997 Apr; 281(1):180-7. PubMed ID: 9103496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Central cholecystokinin activity in irritable bowel syndrome, panic disorder, and healthy controls.
    Koszycki D; Torres S; Swain JE; Bradwejn J
    Psychosom Med; 2005; 67(4):590-5. PubMed ID: 16046372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.